The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2001, Pages 221-226

  Todd, J A ^a   Weston, T ^b   Macdonald, T M ^c   Johnston, D A ^a   Dillon, J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Bureau of Biostatistics and Computer Applications   (Canada)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; FAMOTIDINE; NIZATIDINE; OMEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; DISEASE SEVERITY; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; INCIDENCE; MALE; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

ANTACIDS; BARRETT ESOPHAGUS; CIMETIDINE; ENDOSCOPY; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RANITIDINE;

EID: 0035129608     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00914.x     Document Type: Article

References (52)

1. Oesophageal and gastric cancer in Scotland 1960-90
2. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
3. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
4. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites
5. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus
6. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
7. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
8. Adenocarcinoma and Barrett's esophagus, An overrated risk?
9. The incidence of adenocarcinoma in columnar-lined (Barrett's) Esophagus
10. Increasing incidence of Barrett's oesophagus: Education, enthusiasm or epidemiology?
11. Changing incidence of columnar lined (Barrett's) oesophagus (CLO) in the UK
12. Gastroesophageal reflux and adenocarcinoma of the esophagus
13. Management of Barrett's esophagus free of dysplasia
14. Alkaline gastroesophageal reflux: Implications in the development of complications in Barrett's columnar-lined esophagus
15. Mixed reflux of gastric juice and duodenal juices is more harmful to the esophagus than gastric juices alone, The need for surgical therapy re-emphasized
16. The Tayside Medicines Monitoring Unit (MEMO)
17. The Tayside Medicines Monitoring Unit (MEMO): A record-linkage system for pharmacovigilance
18. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
19. Functional foregut abnormalities in Barrett's esophagus
20. Gastric acidity and gastroesophageal reflux patterns in patients with esophagifts
21. Relationship between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis
22. Effect of cimetidine and antacid on gastric microbial flora
23. Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole
24. Effect of cimetidine on the gastric bacterial flora
25. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study
26. Conventional dose of omeprazole alters gastric flora
27. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites and N-nitroso compounds
28. Alteration of bile acid metabolism by cimetidine in healthy humans
29. Omeprazole induces altered bile acid metabolism
30. Differential effects of deoxycholic acid on proliferation of neoplastic and differentiated colonocytes in vitro
31. Different bile acids exhibit distinct biological effects: The tumour promoter deoxycholic acid induces apoptosis and the chemopreventative agent ursodeoxycholic acid inhibits cell proliferation
32. A bile acid induced apoptosis assay for colon cancer risk and associated quality control studies
33. Risk of carcinoma following gastric operations for benign disease. A study of 3470 patients
34. Gastric carcinogenesis in the rat induced by duodenogastric reflux without carcinogens: Morphology, mucin histochemistry, polyamine metabolism and labelling index
35. Duodenogastric reflux and the development of oesophageal adenocarcinoma in rats
36. Duodenogastric reflux causes growth stimulation of foregut mucosa potentiated by gastric acid blockade
37. Gastric juice protects against the development of esophageal adenocarcinoma in the rat
38. Duodenogastroesophageal reflux and mucosal injury in mechanically ventilated patients
39. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole
40. Prevention of relapse of reflux esophagitis after endoscopic healing: The efficacy and safety of omeprazole compared with ranitidine
41. Five-year cimetidine maintenance trial for peptic ulcer disease: A clinical and endocrinological approach
42. Effects of cimetidine and ranitidine on interdigestive and postprandial lower esophageal sphincter pressures and plasma gastrin levels in normal subjects
43. Mucosal DNA synthesis: A short term index of the trophic action of gastrin
44. New aspects of the trophic action of gastrointestinal hormones
45. Trophic effects of gastrin on colorectal neoplasms in the rat
46. Pentagastrin stimulates in vitro growth of normal and malignant human colon epithelial cells
47. Effects of gastrin, glutamine and somatostatin on the in vitro growth of normal and malignant human gastric mucosal cells
48. Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro
49. Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumour cells
50. Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines
51. Gastrimmune raises antibodies that neutralise amidated and glycine extended Gastrin-17 and inhibit the growth of colon cancer
52. Gastrin - A potential therapeutic target in oesophageal adenocarcinoma and Barrett's oesophagus